All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
21 - 30 of 102 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Beamion™ LUNG-1 and LUNG-2: The zongertinib clinical program in patients with metastatic non-small cell lung cancer and HER2 (ERBB2) mutations
Author(s): Wu et al.
Zongertinib (BI 1810631) in Japanese patients with pretreated HER2 TKD-mutant NSCLC: Beamion™ LUNG-1 Phase Ib Cohort 7
Author(s): Yoshida et al.
Beamion™ BCGC-1: a Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Author(s): Nakayama et al.
Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib in patients with solid tumors with HER2 alterations: focus on Asian patients
Author(s): Yoh et al.
Updated results from the Phase I 1456-0001 study for IT VSV-GP (BI 1831169) in patients with advanced solid tumors
Author(s): Champiat et al.
Systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: Initial results from a Phase Ia study
Author(s): Harrington et al.
Epidemiological and genomic features of patients with advanced/metastatic non-small cell lung cancer with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD)
Author(s): Le et al.
First results for IV VSV-GP (BI 1831169) in patients with advanced solid tumors from the 1456-0001 study
Author(s): Oliva et al.
Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T-cell engager obrixtamig (BI 764532) in patients with DLL3-positive tumors: updated data
Author(s): Wermke et al.
Population Pharmacokinetic/Pharmacodynamic Modelling of Cytokine Releasing Syndrome (CRS) Events During T cell Engager Therapy
Author(s): Kluwe et al.